147 related articles for article (PubMed ID: 38375823)
1. Diagnosis and management of immune mediated liver injury from checkpoint inhibitors.
Likhitsup A; Fontana RJ
Curr Opin Gastroenterol; 2024 May; 40(3):164-171. PubMed ID: 38375823
[TBL] [Abstract][Full Text] [Related]
2. Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development.
Regev A; Avigan MI; Kiazand A; Vierling JM; Lewis JH; Omokaro SO; Di Bisceglie AM; Fontana RJ; Bonkovsky HL; Freston JW; Uetrecht JP; Miller ED; Pehlivanov ND; Haque SA; Harrison MJ; Kullak-Ublick GA; Li H; Patel NN; Patwardhan M; Price KD; Watkins PB; Chalasani NP
J Autoimmun; 2020 Nov; 114():102514. PubMed ID: 32768244
[TBL] [Abstract][Full Text] [Related]
3. Deciphering the Dynamic Complexities of the Liver Microenvironment - Toward a Better Understanding of Immune-Mediated liver Injury Caused by Immune Checkpoint Inhibitors (ILICI).
Wang T; Yeh MM; Avigan MI; Pelosof L; Feldman GM
AAPS J; 2021 Aug; 23(5):99. PubMed ID: 34401948
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of immunosuppressant use for the treatment of immune checkpoint inhibitor-induced liver injury: A systematic review and meta-analysis.
Chen K; He J; Xu J; Chen J
Front Oncol; 2023; 13():1088741. PubMed ID: 37035152
[TBL] [Abstract][Full Text] [Related]
5. [Clinical and pathological characteristics of immune-mediated liver injury caused by immune checkpoint inhibitors].
Zeng YL; Li Y; Tang H; Xu Y; Chen MJ; Li Y; Wang MZ; Tan B; Qian JM
Zhonghua Nei Ke Za Zhi; 2023 Jun; 62(6):700-704. PubMed ID: 37263954
[No Abstract] [Full Text] [Related]
6. Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review.
Ueno M; Takabatake H; Hata A; Kayahara T; Morimoto Y; Notohara K; Mizuno M
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1624. PubMed ID: 35575047
[TBL] [Abstract][Full Text] [Related]
7. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies.
Jennings JJ; Mandaliya R; Nakshabandi A; Lewis JH
Expert Opin Drug Metab Toxicol; 2019 Mar; 15(3):231-244. PubMed ID: 30677306
[TBL] [Abstract][Full Text] [Related]
8. Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology.
Hercun J; Vincent C; Bilodeau M; Lapierre P
Front Immunol; 2022; 13():907591. PubMed ID: 35844534
[TBL] [Abstract][Full Text] [Related]
9. Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors.
Miller ED; Abu-Sbeih H; Styskel B; Nogueras Gonzalez GM; Blechacz B; Naing A; Chalasani N
Am J Gastroenterol; 2020 Feb; 115(2):251-261. PubMed ID: 31789632
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint inhibitor hepatotoxicity: pathogenesis and management.
Cunningham M; Gupta R; Butler M
Hepatology; 2024 Jan; 79(1):198-212. PubMed ID: 36633259
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of tacrolimus in a case of immune checkpoint inhibitor-induced hepatotoxicity that was refractory to steroids and mycophenolate mofetil.
Sato K; Inoue J; Ninomiya M; Iwata T; Sano A; Tsuruoka M; Onuki M; Sawahashi S; Ouchi K; Masamune A
Clin J Gastroenterol; 2023 Oct; 16(5):720-725. PubMed ID: 37480423
[TBL] [Abstract][Full Text] [Related]
12. [Management of immune checkpoint inhibitors-induced liver toxicity in cancer].
Lebossé F; Bancel B; Levrero M; Merle P
Bull Cancer; 2020 Oct; 107(10):1056-1068. PubMed ID: 32951849
[TBL] [Abstract][Full Text] [Related]
13. Clinical and histologic features of Azathioprine-induced hepatotoxicity.
Siramolpiwat S; Sakonlaya D
Scand J Gastroenterol; 2017 Aug; 52(8):876-880. PubMed ID: 28388864
[TBL] [Abstract][Full Text] [Related]
14. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents.
Suzman DL; Pelosof L; Rosenberg A; Avigan MI
Liver Int; 2018 Jun; 38(6):976-987. PubMed ID: 29603856
[TBL] [Abstract][Full Text] [Related]
15. Innate and adaptive immune cell interaction drives inflammasome activation and hepatocyte apoptosis in murine liver injury from immune checkpoint inhibitors.
Shojaie L; Bogdanov JM; Alavifard H; Mohamed MG; Baktash A; Ali M; Mahov S; Murray S; Kanel GC; Liu ZX; Ito F; In GK; Merchant A; Stohl W; Dara L
Cell Death Dis; 2024 Feb; 15(2):140. PubMed ID: 38355725
[TBL] [Abstract][Full Text] [Related]
16. Hepatic immune-mediatedadverseeffects of immune checkpoint inhibitors: analysis of real-life experience.
da Silva JA; Falcão D; Cardoso C; Pires AL; Araújo A; Castro-Poças F
Ann Hepatol; 2021 Dec; 26():100561. PubMed ID: 34653687
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitor-related hepatotoxicity: A review.
Remash D; Prince DS; McKenzie C; Strasser SI; Kao S; Liu K
World J Gastroenterol; 2021 Aug; 27(32):5376-5391. PubMed ID: 34539139
[TBL] [Abstract][Full Text] [Related]
18. The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine.
Fontana RJ; Cirulli ET; Gu J; Kleiner D; Ostrov D; Phillips E; Schutte R; Barnhart H; Chalasani N; Watkins PB; Hoofnagle JH
J Hepatol; 2018 Dec; 69(6):1317-1325. PubMed ID: 30138689
[TBL] [Abstract][Full Text] [Related]
19. Workup and Management of Immune-Mediated Hepatobiliary Pancreatic Toxicities That Develop During Immune Checkpoint Inhibitor Treatment.
Hsu C; Marshall JL; He AR
Oncologist; 2020 Feb; 25(2):105-111. PubMed ID: 32043797
[TBL] [Abstract][Full Text] [Related]
20. Hepatobiliary and Pancreatic Adverse Events.
Zhang HC; Wang LS; Miller E
Adv Exp Med Biol; 2021; 1342():339-355. PubMed ID: 34972973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
